Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor

Hybridoma

Volumn 30, Issue 4, 2011, Pages 347-353

  Kazemi, Tohid ^a   Tahmasebi, Fathollah ^b   Bayat, Ali Ahmad ^b   Mohajer, Neda ^b   Khoshnoodi, Jalal ^a   Jeddi Tehrani, Mahmood ^b   Rabbani, Hodjatallah ^b   Shokri, Fazel ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1B5; MONOCLONAL ANTIBODY 1F2; MONOCLONAL ANTIBODY 1H6; MONOCLONAL ANTIBODY 1H9; MONOCLONAL ANTIBODY 1T0; MONOCLONAL ANTIBODY 2A8; MONOCLONAL ANTIBODY 2A9; MONOCLONAL ANTIBODY 4C7; POLYCLONAL ANTIBODY; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BAGG ALBINO MOUSE; BINDING AFFINITY; CELL CLONING; CELL FUSION; CELL STRAIN 3T3; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYBRIDOMA; INDIRECT ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; MYELOMA CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RECOMBINANT GENE; SPLEEN CELL; STAINING; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TITRIMETRY;

MURINAE; MUS;

EID: 80052004024     PISSN: 15540014     EISSN: 15578348     Source Type: Journal    
DOI: 10.1089/hyb.2011.0023     Document Type: Article

References (32)

1. Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8. (Pubitemid 32938123)
2. Popescu NC, King CR, and Kraus MH: Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4(3):362-366.
3. Ullrich A, and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61(2):203-212.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu onco-gene. Science 1987;235(4785):177-182. (Pubitemid 17231334)
5. Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Han WK, Kim H, Ryu SH, and Sepulveda AR: HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007;22(5): 491-497. (Pubitemid 46488053)
6. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, and Bast RC Jr: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50(13):4087-4091. (Pubitemid 20225635)
7. Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, Berzein K, Moore T, Iannitti D, Reiss P, Pasquariello T, Akerman P, Quirk D, Mass R, Goldstein L, and Tantravahi U: Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001;24(5):496-499. (Pubitemid 32959109)
8. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, and Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20(14):3095-3105. (Pubitemid 34791099)
9. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisa-cane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, and Sliwkowski MX: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2(2):127-137. (Pubitemid 41039113)
10. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, and Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50(5):1550-1558. (Pubitemid 20090470)
11. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89(10): 4285-4289.
12. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, and Pa-pamichail M: Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 2004;53(3):166-175. (Pubitemid 38328039)
13. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, and Sliwkowski MX: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55(6):717-727.
14. Genentech's phase II trial promising for pertuzumab combo in breast cancer. FDA News, Drug Industry Daily, Dec 14, 2010. Available at: http://www.fdanews.com/newsletter/article?articleId 132649&issueId 14296
15. Hajighasemi F, Saboor-Yaraghi AA, and Shokri F: Measurement of affinity constant of anti-human IgG monoclonal antibodies by an ELISA-based method. Iran J Immunol 2004;1(3):154-162.
16. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, and Arribas J: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99(8):628-638. (Pubitemid 47073544)
17. Disis ML, and Cheever MA: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997;71:343-371.
18. Baselga J, and Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies [review]. Ann Oncol 2001;12(Suppl 1):S35-41. (Pubitemid 32750583)
19. Whittington PJ, Radkevich-Brown O, Jacob JB, Jones RF, Weise AM, and Wei WZ: Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Cancer Immunol Immunother 2009;58(5):759-767.
20. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, and Disis ML: Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 2002;9(1):33-44. (Pubitemid 34298362)
21. Baselga J: Treatment of HER2-overexpressing breast cancer [review]. Ann Oncol 2010;21(Suppl 7):vii36-40.
22. Friedlander E, Barok M, Szollosi J, and Vereb G: ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 2008;116(2):126-140.
23. Kawa S, Matsushita H, Ohbayashi H, Semba K, and Ya-mamoto T: A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth. Biochem Biophys Res Commun 2009;384(3):329-333.
24. Masuko T, Sugahara K, Kozono M, Otsuki S, Akiyama T, Yamamoto T, Toyoshima K, and Hashimoto Y: A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product. Jpn J Cancer Res 1989;80(1):10-14. (Pubitemid 20027191)
25. Kametani Y, Shiina M, Katano I, Ito R, Ando K, Toyama K, Tsukamoto H, Matsumura T, Saito Y, Ishikawa D, Taki T, Ito M, Imai K, Tokuda Y, Kato S, Tamaoki N, and Habu S: Development of human-human hybridoma from anti-Her-2 peptide-producing B cells in immunized NOG mouse. Exp Hematol 2006;34(9):1240-1248.
26. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, and Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9(3): 1165-1172. (Pubitemid 19071685)
27. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, and Sela M: A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997;14(17):2099-2109. (Pubitemid 27237013)
28. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(Suppl 12):60-70. (Pubitemid 29411434)
29. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, and Baselga J: Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61(12):4744-4749. (Pubitemid 32691885)
30. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, and Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151(6):1523-1530. (Pubitemid 27527914)
31. Longva KE, Pedersen NM, Haslekas C, Stang E, and Madshus IH: Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005;116(3): 359-367. (Pubitemid 40993331)
32. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, and Vitetta ES: Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002;8(6):1720-1730. (Pubitemid 34633727)